Danmark - dansk - SEGES Landbrug & Fødevarer

cab-dan aps - clopyralid, fluroxypyr, mcpa - flydende middel - 20 g/l clopyralid ; 40 g/l fluroxypyr ; 200 g/l mcpa

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - thyroid neoplasms - antineoplastiske midler - behandling af voksne patienter med progressiv, inoperabel lokalt fremskreden eller metastatisk medullær thyroid carcinoma.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - cabazitaxel - prostatiske neoplasmer - antineoplastiske midler - jevtana i kombination med prednison eller prednisolon er indiceret til behandling af patienter med hormon-ildfast metastatisk prostatacancer, der tidligere er behandlet med en docetaxelholdig behandling.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiske midler - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - dorzolamidhydrochlorid - øjendråber, opløsning - 20 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - travoprost - øjendråber, opløsning - 40 mikrogram/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

infectopharm gmbh - ciprofloxacinhydrochlorid (monohydrat), dexamethason - øredråber, suspension - 3+1 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - dorzolamidhydrochlorid, timololmaleat - øjendråber, opløsning, enkeltdosisbeholder - 20+5 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - latanoprost - øjendråber, opløsning, enkeltdosisbeholder - 50 mikrogram/ml